Joshua Richter, MD from John Theurer Cancer Center discusses CAR-T Cell therapy as potential venue for multiple myeloma and bispecific antibody may provide immuno-oncology in safer venue at the 2017 American Society of Hematology.
CAR-T Cell Therapy as Potential Venue for Multiple Myeloma – Bispecific Antibody may provide immuno-oncology in safer venue
